| Value | ₹2,664 Cr |
|---|
NSE filing, NSE: MAXHEALTH. Summary written from the filing by ALFA Finder's alert engine.
Max Healthcare Institute Ltd: key numbers
- Share price
- ₹860.00
- Market cap
- ₹83,705 Cr
- Revenue (annual)
- ₹8,373 Cr
- Net profit (annual)
- ₹1,442 Cr
- P/E (TTM)
- 57.5×Sector 52.3×
- Promoter holding
- 23.71%+0.00% QoQ
- FII holding
- 40.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Max Healthcare Institute Ltd
All →Max Healthcare Institute Management Change
Max Healthcare appointed Dharmender Kumar as Director and Chief - Public Affairs, effective November 1, 2026. The change was approved at the October 30, 2026 board meeting.
Max Healthcare Institute Capacity Expansion: ₹97 Cr Investment
Max Healthcare will add 60 beds through two new floors at its Vaishali hospital. The Rs.97 Crore project is internally funded and due within 24 months.
- Value
- ₹97.00 Cr
- Execution
- Within 24 months
- hospital beds
- 60.0 beds
Max Healthcare Institute Capacity Expansion: ₹93 Cr Investment
Max Healthcare approved adding about 85 beds at its Noida hospital through redevelopment, at a cost of Rs 93 Crore funded by internal accruals. Commissioning is planned within 15 months.
- Value
- ₹93.00 Cr
- Execution
- Within 15 months
- hospital beds
- 85.0 beds
Max Healthcare Institute Results Update
Max Healthcare Q2 FY27 revenue rose to ₹3,219 Cr, up 20% YoY, with PAT at ₹448 Cr. Board approved ₹415 Cr capex for 209 additional beds.
- hospital beds approved for addition
- 209 beds
Max Healthcare Institute Q2 FY27 Results: Net Profit ₹414.4 Cr, Down 15.7% YoY
Max Healthcare Institute Ltd reported revenue from operations of ₹2,569 Cr (+20.3% YoY) and net profit of ₹414.4 Cr (-15.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹414.4 Cr · -15.7% YoY
Max Healthcare Institute Employee Stock Options
Max Healthcare's NRC approved 95,000 ESOPs at ₹800 exercise price under its 2022 scheme. Vesting spans 1-5 years with a 3-year post-vesting exercise window.
Other results update announcements
All →Crizac Results Update
Crizac reported Q2 FY27 Total Income down 34.5% YoY to ₹1,112 Mn and PAT of ₹369 Mn. An interim dividend of ₹4 per share was declared.
Ind-Swift Laboratories Results Update
Ind-Swift Laboratories reported Q2 FY27 revenue up 50% to ₹234.89 crore and PAT up 3.5x to ₹31.03 crore. Operating EBITDA margin rose to 18.02%.
Syrma SGS Technology Results Update
Syrma SGS reported Q2 FY27 consolidated revenue of Rs.19,995 Mn and PAT of Rs.1,242 Mn. Revenue rose 73% year-on-year, with EBITDA of Rs.2,031 Mn.
Dhanuka Agritech Results Update
Dhanuka Agritech released a press release on its unaudited Q2 FY27 results, reporting profit and revenue growth. The release accompanies the results filing made under Regulation 30.
Lyka Labs Results Update
Q2 FY27 standalone revenue rose 34.06% to Rs. 4,419.95 Lacs. Standalone net profit swung to Rs. 131.50 Lacs from a loss.
Pudumjee Paper Products Results Update
Pudumjee Paper reported half-year turnover of Rs.430 Crore and EBITDA of Rs.90 Crore, up from the prior period. Higher sales tonnage and realisations supported the results.